AcelRx Pharmaceuticals Inc.
| NASDAQ: ACRX | Healthcare / Drug Manufacturers / USA |
| 0.7000 | -0.0199 | -2.76% | Vol 110.08K | 1Y Perf 122.19% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 0.6500 | ASK | 0.7025 | ||
| Open | 0.7180 | Previous Close | 0.7199 | ||
| Pre-Market | - | After-Market | 0.70 | ||
| - - | - -% |
| Target Price | 80.00 | Analyst Rating | — 0.00 | |
| Potential % | 11.33K | Finscreener Ranking | ★★★★★ 63.88 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★+ 49.81 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★★+ 62.60 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.87 | Earnings Rating | Strong Buy | |
| Market Cap | 5.74M | Earnings Date | 30th Mar 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.24 | |
| Beta | 0.60 |
Today's Price Range 0.67000.7180 | 52W Range 0.56877.60 | 5 Year PE Ratio Range -2.00-3.30 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.06% | ||
| 1 Month | -49.64% | ||
| 3 Months | -66.18% | ||
| 6 Months | 191.67% | ||
| 1 Year | 122.19% | ||
| 3 Years | -43.55% | ||
| 5 Years | -66.18% | ||
| 10 Years | -86.64% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 85.79 | |||
ROE last 12 Months | -1 019.81 | |||
ROA (5Y Avg) | -32.32 | |||
ROA last 12 Months | 85.84 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -15.76 | |||
Return on invested Capital Q | -15.76 | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 4.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.60 | ||||
| 11.77 | ||||
| - | ||||
| -0.80 | ||||
| -4.34 | ||||
| 0.97 | ||||
| 3.65 | ||||
| 13.10M | ||||
| Forward PE | -0.22 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.60 | ||||
| 0.10 | ||||
| 0.46 | ||||
| 34.10 | ||||
| Leverage Ratio | 6.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -127.70 | ||||
| 3.21K | ||||
| 3.32K | ||||
| -80 353.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.52M | ||||
| 0.19 | ||||
| 13.11 | ||||
| -22.04 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -1.20 | -0.94 | 21.67 |
| Q02 2022 | -1.20 | -1.20 | 0.00 |
| Q01 2022 | -1.20 | -1.20 | 0.00 |
| Q04 2021 | -1.20 | -1.20 | 0.00 |
| Q03 2021 | -1.40 | -1.40 | 0.00 |
| Q02 2021 | -1.60 | -1.60 | 0.00 |
| Q01 2021 | -0.08 | -0.08 | 0.00 |
| Q04 2020 | -0.12 | -0.10 | 16.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.10 | - | - |
| 12/2022 FY | -3.43 | 4.72 | Positive |
| 3/2023 QR | -1.39 | 0.71 | Positive |
| 12/2023 FY | -2.93 | -1.03 | Negative |
| Next Report Date | 30th Mar 2023 |
| Estimated EPS Next Report | -0.10 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 110.08K |
| Shares Outstanding | 8.20K |
| Shares Float | 145.46M |
| Trades Count | 468 |
| Dollar Volume | 75.89K |
| Avg. Volume | 309.33K |
| Avg. Weekly Volume | 369.42K |
| Avg. Monthly Volume | 333.89K |
| Avg. Quarterly Volume | 224.68K |
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) stock closed at 0.7 per share at the end of the most recent trading day (a -2.76% change compared to the prior day closing price) with a volume of 110.08K shares and market capitalization of 5.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 54 people. AcelRx Pharmaceuticals Inc. CEO is Vincent J. Angotti.
The one-year performance of AcelRx Pharmaceuticals Inc. stock is 122.19%, while year-to-date (YTD) performance is -69.03%. ACRX stock has a five-year performance of -66.18%. Its 52-week range is between 0.5687 and 7.6, which gives ACRX stock a 52-week price range ratio of 1.87%
AcelRx Pharmaceuticals Inc. currently has a PE ratio of 0.30, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 11.77, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 85.84%, a ROC of -15.76% and a ROE of -1 019.81%. The company’s profit margin is -%, its EBITDA margin is 3 322.40%, and its revenue ttm is $1.52 Million , which makes it $0.19 revenue per share.
Of the last four earnings reports from AcelRx Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. AcelRx Pharmaceuticals Inc.’s next earnings report date is 30th Mar 2023.
The consensus rating of Wall Street analysts for AcelRx Pharmaceuticals Inc. is — (0), with a target price of $80, which is +11 328.60% compared to the current price. The earnings rating for AcelRx Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AcelRx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AcelRx Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.11, ATR14 : 0.14, CCI20 : -80.96, Chaikin Money Flow : -0.39, MACD : -0.26, Money Flow Index : 17.53, ROC : -40.17, RSI : 23.62, STOCH (14,3) : 17.53, STOCH RSI : 0.95, UO : 40.50, Williams %R : -82.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AcelRx Pharmaceuticals Inc. in the last 12-months were: Vincent J. Angotti (Buy at a value of $10 333)
AcelRx Pharmaceuticals Inc.
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system) SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for the reduction of moderate-to-severe acute pain in medically supervised settings.
CEO: Vincent J. Angotti
Telephone: +1 650 216-3500
Address: 351 Galveston Drive, Redwood City 94063, CA, US
Number of employees: 54
TipRanks News for ACRX
Wed, 15 Mar 2023 10:31 GMT Analysts Offer Insights on Healthcare Companies: Acelrx (ACRX) and RAPT Therapeutics (RAPT)
- TipRanks. All rights reserved.
